This inventor holds 51 USPTO granted patents and 50 published patent applications, plus 16 CIPO patents and 24 EPO patents, primarily in Guanylate Cyclase Agonists. Top assignees: Synergy Pharmaceuticals, Inc., Bausch Health Ireland Limited, Tiziana Life Sciences Plc. Active years: 2006-2026.
Location History:
- Blue Bell, PA (US) (2006)
- Audobon, PA (US) (2012)
- Audubon, PA (US) (2010 - 2023)
- Line Lexington, PA (US) (2020 - 2024)
Company Filing History:
34 out of 34 
11 out of 45 
4 out of 4 Years Active: 2006-2026
Areas of Expertise:
Title: Innovator Spotlight: Kunwar Shailubhai
Introduction
Kunwar Shailubhai, based in Audubon, PA, is a prolific inventor with an impressive portfolio of 50 patents. His contributions to the field of pharmaceutical sciences and biochemistry have paved the way for advancements in potential treatments for various medical conditions.
Latest Patents
Two of his latest patents exemplify his innovative approach. The first patent, titled "Ultra-pure agonists of guanylate cyclase C, method of making and using same," focuses on processes for purifying a peptide with a GCC agonist sequence. This invention not only emphasizes the solvent exchange step but also includes a freeze-drying (lyophilization) step, showcasing an advanced method for enhancing peptide purity. The second patent, "Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia," presents innovative compositions that utilize dactinomycin formulated for delivery via nanoparticles. It aims to provide novel treatment methodologies for myelodysplastic syndrome and NPM1-mutated acute myeloid leukemia.
Career Highlights
Kunwar Shailubhai has made significant strides in his career through his work at renowned companies such as Synergy Pharmaceuticals, Inc. and Bausch Health Ireland Limited. His tenure at these organizations has honed his skills in drug development and innovation, further solidifying his reputation within the industry.
Collaborations
Throughout his professional journey, Kunwar has collaborated with esteemed colleagues, including Gary S. Jacob and Stephen Comiskey. These partnerships have allowed him to enhance his research capabilities and contribute collectively to the field of medicine.
Conclusion
Kunwar Shailubhai stands out as a true innovator and leader in the pharmaceutical landscape. His dedication to research and development has not only resulted in numerous patents but has also brought forward new possibilities in the treatment of complex medical conditions. His work continues to inspire future inventors and scientists alike.